Numero quattro: Immunology experts at deal-focused IFM line up $55.5M for the next leg of their drug exploration journey

It’s pipeline priming time at IFM Therapeutics. And they have the money to get the job done.

The immunology experts at the discovery outfit have lined up $55.5 million in new venture backing from an expanded syndicate — still including their big believers at Atlas. And it’s not hard to figure out the motivation.